India's Serum Institute has tied up with international vaccine alliance GAVI and the Gates Foundation to produce 100 million doses of the COVID-19 vaccine. Under this deal, Serum will manufacture the vaccines for India and low-and-middle-income countries as early as 2021.
Bill & Melinda Gates Foundation will provide at-risk funding of USD 150 million to GAVI which will transfer the funds to the Serum Institute. The vaccines will be priced at USD 3 per dose. The plan is to make the vaccines available in 92 countries.
So where do we stand in the hunt for a vaccine and how are the various pharma companies and consortiums planning to price it, CNBC-TV18’s Prashant Nair is here with the lowdown.
Brokerages have given a mixed response to the RBI's corporate loan restructuring plan. While Credit Suisse says the magnitude of stress will not be visible till June next year, Macquarie believes that transparency of bank balance sheets has gone for a toss. CNBC-TV18’s Latha Venkatesh apprises on the same.
The government's decision to go for a phased re-opening of the hospitality sector may have brought a ray of hope to many stakeholders, but restaurants in Maharashtra are not feeling the love. CNBC-TV18’s Yash Jain takes stock of the hardships these establishments are facing today.
There's more trouble brewing for exporters -- the government has put on hold registrations for availing benefits under the Merchandise Exports from India Scheme (MEIS). This is a problem for exporters because, under the scheme, a significant portion of duties paid on inputs used for exports is to be reimbursed to exporters. What makes this a bigger problem, is that this decision comes at a time when Indian exports are already in the red.
CNBC-TV18's Rituparna Bhuyan and Timsy Jaipuria visited two small scale units from the engineering and handicraft sectors in the national capital region to get a sense of how India's MSMEs are coping with this sudden policy reversal.